PharmaCyte Biotech, Inc.
PMCB- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001157075
No open-market purchases or sales by PharmaCyte Biotech, Inc. insiders were filed in the last 90 days; 32 institutions reported holding it in 13F filings for Q2 2026, worth $586.2K in total; no superinvestor holds it.
Q1 2026 vs. Q4 2025
How the institutions holding PharmaCyte Biotech, Inc. changed between Q4 2025 and Q1 2026.
All holders in Q1 2026All holders in Q4 2025
| Measure | Q4 2025 | Of which not filed for Q1 2026 | Q1 2026 | Change |
|---|---|---|---|---|
| Holders | 30 | 1 | 36 | +7 |
| Shares | 984.1K | 74.9K | 967.6K | +58.4K (+6.4%) |
| Value | $712.0K | $54.2K | $643.2K | −$14.6K (−2.2%) |
1 institution that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so the changes leave them out.
New holders (11)
Institutions that held PharmaCyte Biotech, Inc. at the end of Q1 2026 but not at the end of Q4 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Vanguard Capital Management LLC | 51,467 | $34.2K | 0.00% |
| Virtu Financial LLC | 37,532 | $25.0K | 0.00% |
| Vanguard Fiduciary Trust Co | 23,452 | $15.6K | 0.00% |
| Ground Swell Capital, LLC | 11,527 | $7.67K | 0.02% |
| Commonwealth Equity Services, LLC | 10,313 | $6.86K | 0.00% |
| Group One Trading, L.P. | 1,785 | $1.19K | 0.00% |
| Harbour Investments, Inc. | 3 | $2 | 0.00% |
| SBI Securities Co., Ltd. | 3 | $2 | 0.00% |
| Johnson Financial Group, Inc. | 1 | $1 | 0.00% |
| Abound Wealth Management | 1 | $1 | 0.00% |
| Fortitude Family Office, LLC | 1 | $1 | 0.00% |
Sold out (4)
Institutions that held PharmaCyte Biotech, Inc. at the end of Q4 2025 and filed for Q1 2026 without it.
| Institution | Shares, Q4 2025 | Value, Q4 2025 |
|---|---|---|
| Sabby Management, LLC | 100,000 | $72.4K |
| Bank of America Corp | 314 | $227 |
| Aviso Financial Inc. | 12 | $8 |
| IFP Advisors, Inc | 1 | $1 |
Not filed for Q1 2026 yet (1)
Institutions that held PharmaCyte Biotech, Inc. at the end of Q4 2025 and haven't filed a 13F for Q1 2026. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2025 | Value, Q4 2025 |
|---|---|---|
| Vanguard Group Inc | 74,919 | $54.2K |